Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH - Get Free Report) major shareholder Financial Lp Hrt acquired 8,266 shares of the firm's stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average price of $3.38 per share, with a total value of $27,939.08. Following the completion of the acquisition, the insider owned 60,540 shares of the company's stock, valued at $204,625.20. This represents a 15.81% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Friday, July 10th, Financial Lp Hrt bought 731 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.11 per share, for a total transaction of $2,273.41.
- On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $65,229.12.
- On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.33, for a total value of $35,231.40.
- On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
- On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.54 per share, with a total value of $27,792.54.
- On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.30 per share, for a total transaction of $13,064.70.
- On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.23 per share, for a total transaction of $21,818.65.
- On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.44 per share, with a total value of $88,875.84.
Shuttle Pharmaceuticals Trading Up 1.4%
Shares of SHPH opened at $2.96 on Tuesday. The stock has a market capitalization of $1.89 million, a price-to-earnings ratio of -0.06 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.71 and a 12 month high of $55.90. The firm has a fifty day simple moving average of $4.86 and a 200 day simple moving average of $9.96.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at about $357,000. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the fourth quarter worth approximately $26,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth approximately $124,000. Institutional investors and hedge funds own 4.58% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently commented on SHPH. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a "sell (e)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Wall Street Zen raised Shuttle Pharmaceuticals to a "sell" rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of "Sell".
Read Our Latest Research Report on SHPH
Shuttle Pharmaceuticals Company Profile
(
Get Free Report)
Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
